Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial)

Neuroscience and Behavioral Physiology

Volumn 38, Issue 9, 2008, Pages 933-936

  Boiko, A N ^a,b,c,d   Batysheva, T T ^a,b,c,d   Minaeva, N G ^a,b,c,d   Babina, L A ^a,b,c,d   Vdovichenko, T V ^a,b,c,d   Zhuravleva, E Y U ^a,b,c,d   Shikhkerimov, R K ^a,b,c,d   Malykhina, E A ^a,b,c,d   Khozova, A A ^a,b,c,d   Zaitsev, K A ^a,b,c,d   Kostenko, E V ^a,b,c,d  

^a PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^b Rehabilitation Polyclinic No 7   (Russian Federation)

^c A I EVDOKIMOV MOSCOW STATE UNIVERSITY OF MEDICINE AND DENTISTRY   (Russian Federation)

^d Moscow Regional Neurology Departments   (Russian Federation)

Author keywords

"wearingoff"phenomenon; COMT; Constant dopaminergic stimulation; Entacapone; Fluctuation; Parkinson's disease; Stalevo

Indexed keywords

CARBIDOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; ENTACAPONE; LEVODOPA;

AGED; ARTICLE; BALANCE DISORDER; CLINICAL TRIAL; DISEASE DURATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERABILITY; DYSKINESIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; NAUSEA; ORTHOSTATIC HYPOTENSION; OUTPATIENT; PARKINSON DISEASE; RUSSIAN FEDERATION; SINGLE DRUG DOSE; TREATMENT DURATION;

ACTIVITIES OF DAILY LIVING; AGED; ANTIPARKINSON AGENTS; CARBIDOPA; CATECHOLS; DRUG COMBINATIONS; DYSKINESIAS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MOTOR ACTIVITY; OUTPATIENTS; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 56249139362     PISSN: 00970549     EISSN: 1573899X     Source Type: Journal    
DOI: 10.1007/s11055-008-9085-3     Document Type: Article

References (22)

1. A. N. Boiko, T. T. Batysheva, E. S. Chikina, et al., "Experience in the use of dopamine receptor agonists in the out-patient treatment of Parkinson's disease," Zh. Nevrol. Psikhiat., 103, No. 9, 54-58 (2003).
2. A. N. Boiko, T. T. Batysheva, E. S. Chikina, et al., "Use of Tremonorm in Parkinson's disease: Experience of the out-patient neurological service of the Moscow City Health System," Zh. Nevrol. Psikhiat., 104, No. 12, 23-28 (2004).
3. A. N. Boiko, T. T. Batysheva, E. S. Chikina, et al., "Efficacy of PK-Merz in Parkinson's disease in out-patient practice," Lech. Nerv. Bolezn., 2, 23-27 (2005).
4. V. L. Golubev, Ya. I. Levin, and A. M. Vein, Parkinson's disease and Parkinson's Syndrome [in Russian], Medpress, Moscow (1999).
5. V. L. Golubev and A. A. Palipovich, "New possibilities in the treatment of Parkinson's disease with Stalevo (levodopa/carbidopa/ entacapone)," Lech. Nerv. Bolezn., 1, 1-11 (2006).
6. O. S. Levin, "Development of motor fluctuations in patients with different stages of Parkinson's disease," Atmosfera (Nerv. Bolezn., 1, 10-16 (2005).
7. O. S. Levin and N. V. Fedorova, Parkinson's disease [in Russian], Moscow (2006).
8. N. V. Fedorova, O. V. Krivonos, I. P. Chigir', et al., "Use of catechol-O-methyltransferase (COMT) inhibitors in the treatment of the late stages of Parkinson's disease," Kreml. Med., 2, 66-72 (2001).
9. N. V. Fedorova, O. S. Levin, I. G. Smolentseva, et al., "A new-generation levodopa preparation " Stalevo (levodopa/carbidopa/ entacapone), in the treatment of Parkinson's disease," Zh. Nevrol. Psikhiat., 9, 39-46 (2006).
10. V. N. Shtok, and N. V. Fedorova, Parkinson's disease. Extrapyramidal Disorders. Handbook for Diagnosis and Treatment [in Russian], Medpress-Inform, Moscow (2002), pp. 87-124.
11. D. Brooks, H. Sagar, and the UK-Irish Entacapone study group, "Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease. A randomized, placebo-controlled, double-blind six-month study," J. Neurol. Neurosurg. Psychiat., 74, 1064-1072 (2003).
12. D. Brooks, Y. Agid, K. Eggert, et al., "NC-INIT Study Group. Treatment of end-of-dose wearing-off in Parkinson's disease: Stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment," Eur. Neurol., 53, No. 4, 197-202 (2005).
13. P. Jenner, "Avoidance of dyskinesia: Preclinical evidence for continuous dopaminergic stimulation," Neurology, 62, Supplement 1, 47-55 (2004).
14. T. Müller, C. Erdmann, S. Muhlack, et al., "Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels," Mov. Dis., 21, No. 3, 332-336 (2006).
15. D. Nyholm, A. I. Nilsson Remahl, N. Disdar, et al., "Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease," Neurology, 64, No. 2, 216-223 (2005).
16. C. W. Olanow, K. Kieburtz, M. Stern, et al., "Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease," Arch. Neurol., 61, No. 10, 1563-1568 (2004).
17. C. W. Olanow and F. Stocchi, "COMT inhibitors in Parkinson's disease: Can they prevent and/or reverse levodopa-induced motor complications?" Neurology, 62, Supplement 1, 72-81 (2004).
18. R. Pahwa, K. Lyons, D. McGuire, et al., "Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: Pharmacokinetic and quality-of-life measures," Mov. Dis., 12, No. 5, 677-681 (1997).
19. W. Poewe and G. Wenning, "Levodopa in Parkinson's Disease: mechanisms of action and pathophysiology of late failure," in: Parkinson's Disease, Movement Disorders, J. J. Jankovic and E. Tolosa (eds.) (2002), pp. 104-115.
20. W. H. Poewe, G. Deuschl, A. Gardin, et al., "Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: A 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study)," Acta Neurol. Scand., 105, 245-255 (2002).
21. A. H. Schapiro and J. Obeso, "Timing of treatment initiation in Parkinson's disease: A need for reappraisal," Ann. Neurol., 59, No. 3, 559-562 (2006).
22. A. Schrag, "Entacapone in the treatment of Parkinson's disease," Lancet. Neurol., 4, No. 6, 366-370 (2005).